Technical Analysis for VNRX - VolitionRX Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.62 | 2.31% | 0.01 |
Earnings due: Jul 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 2.31% | |
| BB Squeeze Ended | Range Expansion | 2.31% | |
| Below Lower BB | Weakness | 2.31% | |
| Lower Bollinger Band Touch | Weakness | 2.31% | |
| Oversold Stochastic | Weakness | 2.31% |
| Alert | Time |
|---|---|
| Gapped Up (Partial) | about 10 hours ago |
| Rose Above Lower Bollinger Band | about 10 hours ago |
| Up 3% | about 10 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
| Up 2% | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 07/02/2024
VolitionRX Limited Description
VolitionRX Limited, a development stage life sciences company, focuses on developing cancer detection blood tests for detecting and diagnosing cancer and other diseases. It develops two blood tests in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer and nucleosomes containing specific histone variants. The company also develops nine blood tests in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones, the proteins that package, and order DNA into nucleosomes; and five blood tests in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts, as well as offers research kits. It develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help appropriate therapy; NuQ Endo endometriosis test; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Cancer Biology Disease Molecular Biology Genomics Diagnostic Products Blood Test Epigenetics Endometriosis Cancer Detection Nucleotides
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.55 |
| 52 Week Low | 0.55 |
| Average Volume | 195,517 |
| 200-Day Moving Average | 0.82 |
| 50-Day Moving Average | 0.74 |
| 20-Day Moving Average | 0.67 |
| 10-Day Moving Average | 0.65 |
| Average True Range | 0.05 |
| RSI (14) | 41.18 |
| ADX | 11.85 |
| +DI | 12.28 |
| -DI | 19.50 |
| Chandelier Exit (Long, 3 ATRs) | 0.59 |
| Chandelier Exit (Short, 3 ATRs) | 0.76 |
| Upper Bollinger Bands | 0.74 |
| Lower Bollinger Band | 0.60 |
| Percent B (%b) | 0.13 |
| BandWidth | 21.50 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.0043 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.66 | ||||
| Resistance 3 (R3) | 0.66 | 0.65 | 0.66 | ||
| Resistance 2 (R2) | 0.65 | 0.64 | 0.65 | 0.65 | |
| Resistance 1 (R1) | 0.63 | 0.63 | 0.63 | 0.63 | 0.65 |
| Pivot Point | 0.62 | 0.62 | 0.62 | 0.62 | 0.62 |
| Support 1 (S1) | 0.60 | 0.61 | 0.60 | 0.60 | 0.59 |
| Support 2 (S2) | 0.59 | 0.60 | 0.59 | 0.58 | |
| Support 3 (S3) | 0.57 | 0.59 | 0.58 | ||
| Support 4 (S4) | 0.57 |
